Impact of Glycoprotein IIb/IIIa Inhibition in Contemporary Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the National Cardiovascular Data Registry

JACC: Cardiovascular Interventions

Volumn 8, Issue 12, 2015, Pages 1574-1582

  Safley, David M ^a,b   Venkitachalam, Lakshmi ^c   Kennedy, Kevin F ^a   Cohen, David J ^a,b  

^a SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute coronary syndrome; glycoprotein IIb IIIa antagonist; myocardial infarction; percutaneous coronary intervention

Indexed keywords

CLOPIDOGREL; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ACUTE CORONARY SYNDROME; ANALYTIC METHOD; ANTICOAGULATION; ARTICLE; BLEEDING DISORDER; CARDIOVASCULAR MORTALITY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; BLEEDING; BLOOD; CAUSE OF DEATH; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; HOSPITAL MORTALITY; METABOLISM; MULTIVARIATE ANALYSIS; ODDS RATIO; PROPENSITY SCORE; REGISTER; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; HEMORRHAGE; HEPARIN; HOSPITAL MORTALITY; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROPENSITY SCORE; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84945555972     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2015.04.031     Document Type: Article

References (39)

1. Canadian Cardiovascular Society, American Academy of Family Physicians, American College of Cardiology/American Heart Association E.M. Antman, M. Hand, P.W. Armstrong, and et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 51 2008 210 247
2. H. Jneid, J.L. Anderson, R.S. Wright, and et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 60 2012 645 681
3. P.T. O'Gara, F.G. Kushner, D.D. Ascheim, and et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 e78 e140
4. M.B. Kadakia, N.R. Desai, K.P. Alexander, and et al. Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry-GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines) J Am Coll Cardiol Intv 3 2010 1166 1177
5. D.W. Mudrick, A.Y. Chen, M.T. Roe, and et al. Changes in glycoprotein IIb/IIIa inhibitor excess dosing with site-specific safety feedback in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) initiative Am Heart J 160 2010 1072 1078
6. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation N Engl J Med 330 1994 956 961
7. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization N Engl J Med 336 1997 1689 1696
8. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade Lancet 352 1998 87 92
9. J.C. O'Shea, G.E. Hafley, S. Greenberg, and et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial JAMA 285 2001 2468 2473
10. J.B. Lindsey, K.F. Kennedy, J.M. Stolker, and et al. Prognostic implications of creatine kinase-MB elevation after percutaneous coronary intervention: results from the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry Circ Cardiovasc Interv 4 2011 474 480
11. J.B. Lindsey, S.P. Marso, M. Pencina, and et al. Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry J Am Coll Cardiol Intv 2 2009 1074 1082
12. I.D. Moussa, L.W. Klein, B. Shah, and et al. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI) J Am Coll Cardiol 62 2013 1563 1570
13. S.B. King 3rd, S.C. Smith Jr., J.W. Hirshfeld Jr., and et al. 2007 Focused update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 51 2008 172 209
14. G. Tomlinson, and A.S. Detsky Composite end points in randomized trials: there is no free lunch JAMA 303 2010 267 268
15. D.E. Kandzari, M.T. Roe, A.Y. Chen, and et al. Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes Am Heart J 149 2005 474 481
16. R.P. Giugliano, J.A. White, C. Bode, and et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes N Engl J Med 360 2009 2176 2190
17. A. Kastrati, F.J. Neumann, S. Schulz, and et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction N Engl J Med 365 2011 1980 1989
18. R.J. Bowden, and D.A. Turkington Instrumental Variables 1984 Cambridge University Press Cambridge, MA
19. M. McClellan, B.J. McNeil, and J.P. Newhouse Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables JAMA 272 1994 859 866
20. L. Venkitachalam, Y. Lei, E.A. Magnuson, and et al. Survival benefit with drug-eluting stents in observational studies: fact or artifact? Circ Cardiovasc Qual Outcomes 4 2011 587 594
21. CathPCI Registry. Available at: https://www.ncdr.com/webncdr/cathpci/home/datacollection. Accessed September 10, 2015.
22. P.R. Rosenbaum, and D.B. Rubin Constructing a control group using multivariate matched sampling methods that incorporate the propensity score Am Stat 39 1985 6
23. J.P. Newhouse, and M. McClellan Econometrics in outcomes research: the use of instrumental variables Annu Rev Public Health 19 1998 17 34
24. J.A. Rassen, M.A. Mittleman, R.J. Glynn, M. Alan Brookhart, and S. Schneeweiss Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention Eur Heart J 31 2009 561 572
25. J.W. Ryan, E.D. Peterson, A.Y. Chen, and et al. Optimal timing of intervention in non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Registry Circulation 112 2005 3049 3057
26. T.A. Stukel, E.S. Fisher, D.E. Wennberg, D.A. Alter, D.J. Gottlieb, and M.J. Vermeulen Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods JAMA 297 2007 278 285
27. M.A. Brookhart, and S. Schneeweiss Preference-based instrumental variable methods for the estimation of treatment effects: assessing validity and interpreting results Int J Biostat 3 2007 14
28. S.L. Morgan, and D.J. Harding Matching estimators of causal effects: prospects and pitfalls in theory and practice Sociol Methods Res 35 2006 3 60
29. D.Y. Lin, B.M. Psaty, and R.A. Kronmal Assessing the sensitivity of regression results to unmeasured confounders in observational studies Biometrics 54 1998 948 963
30. S.K. Mehta, A.D. Frutkin, J.B. Lindsey, and et al. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry Circ Cardiovasc Interv 2 2009 222 229
31. S.V. Rao, L.A. McCoy, J.A. Spertus, and et al. An updated bleeding model to predict the risk of post-procedure bleeding among patients undergoing percutaneous coronary intervention: a report using an expanded bleeding definition from the National Cardiovascular Data Registry CathPCI Registry J Am Coll Cardiol Intv 6 2013 897 904
32. E.D. Peterson, D. Dai, E.R. DeLong, and et al. Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry J Am Coll Cardiol 55 2010 1923 1932
33. J.V. Tu, and D.T. Ko Ecological studies and cardiovascular outcomes research Circulation 118 2008 2588 2593
34. V. Prasad, and A.B. Jena Prespecified falsification end points: can they validate true observational associations? JAMA 309 2013 241 242
35. E. Boersma, R.A. Harrington, D.J. Moliterno, H. White, and M.L. Simoons Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes Lancet 360 2002 342 343
36. A. Sethi, A. Bajaj, A. Bahekar, and et al. Glycoprotein IIb/IIIa inhibitors with or without thienopyridine pretreatment improve outcomes after primary percutaneous coronary intervention in high risk patients with ST elevation myocardial infarction-a meta-regression of randomized controlled trials Catheter Cardiovasc Interv 82 2013 171 181
37. D.E. Winchester, W.D. Brearley, X. Wen, K.E. Park, and A.A. Bavry Efficacy and safety of unfractionated heparin plus glycoprotein IIb/IIIa inhibitors during revascularization for an acute coronary syndrome: a meta-analysis of randomized trials performed with stents and thienopyridines Clin Cardiol 35 2012 93 100
38. G.W. Stone, B.T. McLaurin, D.A. Cox, and et al. Bivalirudin for patients with acute coronary syndromes N Engl J Med 355 2006 2203 2216
39. G.W. Stone, B. Witzenbichler, G. Guagliumi, and et al. Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2008 2218 2230